What Is GLP-2 Studied For? Research Areas, Per the Literature

Answer first: what the literature studies GLP-2 for

GLP-2 is not approved by the FDA as a medicine for any condition. This page is not guidance. The question "what is GLP-2 used for" is answered here only as "what has GLP-2 been studied for," organised by research area, with the study type and population named beside each citation. A separate regulatory fact is relevant for context: teduglutide, a long acting GLP-2 receptor agonist analogue, exists as a prescription product and has its own clinical literature in short bowel syndrome, which a 2020 pharmacotherapy review described as a strategy aimed at reducing dependence on parenteral support (PMID 32057270). Native GLP-2 itself and research grade GLP-2 peptides are not approved medicines.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health condition or any decision involving a medicine or a hormone.

What GLP-2 is, according to review literature

A 2006 review in Annual Review of Nutrition described GLP-2 as a proglucagon derived peptide released from intestinal enteroendocrine L cells, with intestinotrophic actions on the intestinal mucosa and effects on nutrient absorption and mucosal integrity (PMID 16602931). That review is narrative, not a trial, and its scope is physiology rather than treatment outcomes (PMID 16602931). Because GLP-2 arises from the same proglucagon precursor as GLP-1 and glucagon, model systems built for pancreatic alpha cell research are also part of this field; a 2021 report in Islets described a novel mouse model intended to expand study of human alpha cells, which process proglucagon derived peptides (PMID 33853502).

Research area map

1. Short bowel syndrome and intestinal adaptation

This is the research area where GLP-2 biology has travelled furthest toward human data. A 2020 review of pharmacotherapy for short bowel syndrome placed GLP-2 analogue therapy among the pharmacological approaches studied for intestinal rehabilitation in patients dependent on parenteral nutrition (PMID 32057270). The mechanistic rationale traces back to the intestinotrophic properties of GLP-2 described in physiology reviews, where researchers summarised mucosal growth and absorptive effects (PMID 16602931).

Children with short bowel syndrome

A 2021 expert review examined teduglutide specifically in pediatric short bowel syndrome patients, covering the available clinical evidence and the practical considerations raised in that population (PMID 33798402). A review of this kind summarises trials rather than generating new outcome data, so it should be read as an evidence synthesis for a specific patient group, not as a general statement about GLP-2 peptides (PMID 33798402).

Anatomy matters: the colon in continuity

A 2023 review in Nutrients examined the role of a colon in continuity in short bowel syndrome, discussing how remaining colonic anatomy influences fluid and energy handling and the endocrine environment of the remnant bowel (PMID 36771335). That review is relevant to GLP-2 research because L cells, the source of GLP-2 described in physiology reviews, are concentrated in the distal gut (PMID 16602931), so anatomy defines part of the study population in this field (PMID 36771335).

2. Intestinal barrier and inflammatory intestinal disease

Interest in gut hormones for intestinal disease is broad, but the review literature is weighted toward GLP-1. A 2021 Biomedicines review surveyed GLP-1 in intestinal diseases rather than GLP-2, which illustrates how much of the gut hormone evidence base in this area has been built around the sister peptide (PMID 33916501). For GLP-2 itself, the mucosal and barrier related actions reported in physiology reviews remain the main reference point (PMID 16602931), and controlled human outcome trials in inflammatory bowel disease are not represented in the verified literature on this page.

3. Liver disease and the gut liver axis

GLP-2 has been studied as one half of dual agonist molecules rather than only as a standalone peptide. A 2022 Hepatology report described a GLP-1 and GLP-2 receptor dual agonist developed for nonalcoholic steatohepatitis, with the stated strategy of targeting the gut liver axis and the microbiome (PMID 34773257). The study is framed around mechanism and drug development; it does not establish long term clinical liver outcomes for GLP-2 in humans (PMID 34773257).

4. Antipsychotic associated metabolic dysfunction (animal only)

A 2025 study in Nature Metabolism reported that GLP-2 prevented antipsychotic induced metabolic dysfunction in mice, making this an animal model finding in rodents rather than a human result (PMID 40114026). Researchers working in this area investigated a gut hormone route to metabolic side effects of antipsychotic drugs, and the authors of that mouse study framed GLP-2 as a candidate mechanism (PMID 40114026). No human trial for this indication appears in the verified citation set, so the honest status is preclinical.

5. Bone: review level and indirect only

A 2025 review in the International Journal of Molecular Sciences covered updates on diabetes and bone, a literature in which gut derived hormones are discussed alongside glycaemic and skeletal outcomes (PMID 40943066). Separately, a 2023 Gut Microbes study reported that Lactobacillus rhamnosus GG ameliorated osteoporosis in ovariectomized rats by regulating the Th17 and Treg balance and gut microbiota structure, an animal study of the gut bone axis rather than a study of GLP-2 administration (PMID 36941563). Stated plainly: the verified literature here does not contain a human trial of GLP-2 for bone density or fracture outcomes.

6. Heart and the gut axis: indirect evidence

A 2023 Cardiovascular Research study reported that heart and gut microbiota communication determined the severity of cardiac injury after myocardial ischaemia and reperfusion, work conducted in a rodent ischaemia reperfusion model (PMID 36715640). That study belongs to the broader gut organ axis field that makes intestinal hormones a research interest, but it is an animal study and it does not demonstrate a cardiac use for GLP-2 in people (PMID 36715640).

7. Diet, glycaemic control and satiety

Nutrition research sometimes measures gut hormone responses to foods. A systematic review published in 2024 examined consumption of sourdough bread and changes in glycaemic control and satiety in human studies, and the review's endpoints were glycaemic and satiety outcomes rather than GLP-2 specific clinical results (PMID 35943419). It is included here because dietary stimulation of L cell hormones, described as the source of GLP-2 in physiology reviews (PMID 16602931), is a recurring research theme, not because that review established an effect of GLP-2 itself (PMID 35943419).

Adverse Events: What Studies Report

The verified literature on this page does not contain a dedicated safety trial of native GLP-2 in healthy humans. What it does contain is clinical review material on a GLP-2 analogue: the 2021 pediatric review of teduglutide in short bowel syndrome discussed the clinical evidence including safety considerations in that patient group (PMID 33798402), and the 2020 pharmacotherapy review similarly covered the place of GLP-2 analogue therapy alongside other agents used in short bowel syndrome management (PMID 32057270). Because the hormone is intestinotrophic, meaning it promotes growth of intestinal mucosa as described in review literature (PMID 16602931), proliferative effects are a recognised topic in that clinical literature (PMID 33798402). No dose figures are reproduced on this page because the verified citation set does not support specific dosing statements.

Where the evidence is weak or absent

• Weight loss in otherwise healthy adults: not represented in the verified literature. The nearest metabolic finding is a mouse study of antipsychotic associated metabolic dysfunction (PMID 40114026).
• Leaky gut as a consumer category: barrier and mucosal actions are described at the physiology level in review form (PMID 16602931), without human outcome trials in this citation set.
• Bone or joint outcomes: review level discussion of diabetes and bone (PMID 40943066) and an ovariectomized rat probiotic study (PMID 36941563) do not amount to GLP-2 evidence for bone.
• Liver disease: a dual agonist development report targeting the gut liver axis (PMID 34773257) is mechanistic work, not a completed clinical outcome programme.
• Cardiac protection: the gut heart axis study was an animal model and did not test GLP-2 as a therapy (PMID 36715640).

How to read study types on this page

1. In vitro and cell or model systems: useful for mechanism, such as the alpha cell model report describing tools for proglucagon biology (PMID 33853502).
2. Animal studies: hypothesis generating, as in the mouse study of GLP-2 and antipsychotic induced metabolic dysfunction (PMID 40114026).
3. Human clinical literature and reviews: the most directly applicable material, concentrated in short bowel syndrome (PMID 32057270, PMID 33798402).

Related reading

For the background overview of this peptide, see the hub page at /learn/glp-2/.

Closing

GLP-2 is not approved by the FDA as a medicine for any condition. This page is not guidance. The strongest human relevant literature summarised above sits in short bowel syndrome and intestinal adaptation (PMID 32057270, PMID 36771335), while other research areas remain preclinical or review level (PMID 40114026). This page is for educational purposes only and is not medical advice; consult a licensed physician for any individual question about health, diagnosis or treatment.

References

• Glucagon-like Peptide-2 (Annual Review of Nutrition, 2006)
• Treating short bowel syndrome with pharmacotherapy (Expert Opinion on Pharmacotherapy, 2020)
• Teduglutide for pediatric short bowel syndrome patients (Expert Review of Gastroenterology and Hepatology, 2021)
• The Role of a Colon-in-Continuity in Short Bowel Syndrome (Nutrients, 2023)
• GLP-1 and Intestinal Diseases (Biomedicines, 2021)
• A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome (Hepatology, 2022)
• GLP-2 prevents antipsychotics-induced metabolic dysfunction in mice (Nature Metabolism, 2025)
• Novel mouse model expands potential human alpha-cell research (Islets, 2021)
• Recent Updates on Diabetes and Bone (International Journal of Molecular Sciences, 2025)
• Lactobacillus rhamnosus GG ameliorates osteoporosis in ovariectomized rats by regulating the Th17/Treg balance and gut microbiota structure (Gut Microbes, 2023)
• Heart-gut microbiota communication determines the severity of cardiac injury after myocardial ischaemia/reperfusion (Cardiovascular Research, 2023)
• Consumption of sourdough bread and changes in the glycemic control and satiety: A systematic review (Critical Reviews in Food Science and Nutrition, 2024)